<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Standing</title>
	<atom:link href="http://www.tapanray.in/tag/standing/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Against Pharma Marketing Malpractices: A Gutsy Step</title>
		<link>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=against-pharma-marketing-malpractices-a-gutsy-step</link>
		<comments>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/#comments</comments>
		<pubDate>Mon, 22 Feb 2016 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[58th]]></category>
		<category><![CDATA[BBC]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Clinton]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[conflit]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dollars for doc]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[follow]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Gutsy]]></category>
		<category><![CDATA[Hilary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharnaceuticals]]></category>
		<category><![CDATA[Physician Payments Sunshine Act]]></category>
		<category><![CDATA[ProPublica]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7447</guid>
		<description><![CDATA[January 7, 2016 edition of ‘The Financial Times (FT)’ reported that responding to escalating pressure on the drug industry, related to its ‘Conflict of Interest’ with the doctors and other related professionals, GlaxoSmithKline (GSK) has decided taking a very unorthodox &#8230; <a href="http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Booming Sales Of Unapproved Drugs: Do We Need “Safe In India” Campaign For Medicines?</title>
		<link>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines</link>
		<comments>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/#comments</comments>
		<pubDate>Mon, 18 May 2015 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Abraham]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[booming]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[journal]]></category>
		<category><![CDATA[Lincoln]]></category>
		<category><![CDATA[may]]></category>
		<category><![CDATA[medicines. PLOS]]></category>
		<category><![CDATA[mission]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Peer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reviewed]]></category>
		<category><![CDATA[Safe in India]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Statement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unapproved]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6622</guid>
		<description><![CDATA[“To sin by silence when they should protest makes cowards of men”                      - Abraham Lincoln Not just the Federal Drug Administration of the United States (USFDA), global concerns are being expressed &#8230; <a href="http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/booming-sales-of-unapproved-drugs-do-we-need-safe-in-india-campaign-for-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does ‘Free-Market Economy’ Work For Branded Generic Drugs In India?</title>
		<link>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-free-market-economy-work-for-branded-generic-drugs-in-india</link>
		<comments>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/#comments</comments>
		<pubDate>Mon, 27 Apr 2015 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Badm Medicine]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[chemicals. and. fertilizers]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Delhi School of Economics]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DSE]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Free Market Economy]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[IJME]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[paradox]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[‘Dorfman-Steiner’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6557</guid>
		<description><![CDATA[On April 20, 2015, a panel of 31 lawmakers of the Standing Committee on Chemicals and Fertilizers tabled its report in the Indian Parliament. The committee emphasized that patients in India should have access to all medicines, including life saving drugs, &#8230; <a href="http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI: Damning Report of Parliamentary Panel, PM Vetoes&#8230;and Avoids Ruffling Feathers?</title>
		<link>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers</link>
		<comments>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/#comments</comments>
		<pubDate>Mon, 19 Aug 2013 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Discussion]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[feathers]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illusionary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[matrix]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[oligopolistic]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[protectionism]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[restriction]]></category>
		<category><![CDATA[retrograde]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tweaking]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[vetoed]]></category>
		<category><![CDATA[vetoes veto]]></category>
		<category><![CDATA[wrong]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3241</guid>
		<description><![CDATA[An interesting situation emerged last week. The Parliamentary Standing Committee (PSC) on Commerce proposed a blanket ban on all FDI in brownfield pharma sector. Just two days after that, the Prime Minister of India vetoed the joint opposition of the Department &#8230; <a href="http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-damning-report-of-parliamentary-panel-pm-vetoes-and-avoids-ruffling-feathers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Slugfest in Pharma Land: Isn&#8217;t &#8216;The Pot Calling the Kettle Black?&#8217;</title>
		<link>http://www.tapanray.in/slugfest-in-pharma-land-isnt-the-pot-calling-the-kettle-black/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=slugfest-in-pharma-land-isnt-the-pot-calling-the-kettle-black</link>
		<comments>http://www.tapanray.in/slugfest-in-pharma-land-isnt-the-pot-calling-the-kettle-black/#comments</comments>
		<pubDate>Mon, 29 Jul 2013 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Barometer]]></category>
		<category><![CDATA[bells]]></category>
		<category><![CDATA[Black]]></category>
		<category><![CDATA[bribe]]></category>
		<category><![CDATA[bribery]]></category>
		<category><![CDATA[calling]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Collusive]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Institutions]]></category>
		<category><![CDATA[intolerance]]></category>
		<category><![CDATA[kettle]]></category>
		<category><![CDATA[KPMG]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Panel]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pot]]></category>
		<category><![CDATA[quotient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[scientist]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[slugfest]]></category>
		<category><![CDATA[smoke]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tolerance]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3022</guid>
		<description><![CDATA[Close on the heels of detention of a British Citizen, an American citizen too has  been reportedly detained, for the first time, by the Chinese Government in connection with unfolding mega corruption scandal in the country&#8217;s pharma industry involving even &#8216;third party&#8217;. A slugfest &#8230; <a href="http://www.tapanray.in/slugfest-in-pharma-land-isnt-the-pot-calling-the-kettle-black/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/slugfest-in-pharma-land-isnt-the-pot-calling-the-kettle-black/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Small Steps, yet Giant Leaps: In Pursuit of Affordable Medicines for All</title>
		<link>http://www.tapanray.in/small-steps-yet-giant-leaps-in-pursuit-of-affordable-medicines-for-all/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=small-steps-yet-giant-leaps-in-pursuit-of-affordable-medicines-for-all</link>
		<comments>http://www.tapanray.in/small-steps-yet-giant-leaps-in-pursuit-of-affordable-medicines-for-all/#comments</comments>
		<pubDate>Mon, 01 Apr 2013 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[empowerment]]></category>
		<category><![CDATA[Forbes]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Improving]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[leaps]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Obamacare]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[SMS]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[steps]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2116</guid>
		<description><![CDATA[Since last few years, some small yet very significant steps are being taken, mostly by the respective Governments, in and outside India, to provide affordable healthcare in general and affordable medicines in particular, for all. It is well recognized that &#8230; <a href="http://www.tapanray.in/small-steps-yet-giant-leaps-in-pursuit-of-affordable-medicines-for-all/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/small-steps-yet-giant-leaps-in-pursuit-of-affordable-medicines-for-all/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To Curb Pharma Marketing Malpractices in India Who Bells the Cat?</title>
		<link>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat</link>
		<comments>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/#comments</comments>
		<pubDate>Mon, 18 Mar 2013 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bribe]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[curb]]></category>
		<category><![CDATA[curbing]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[E&Y]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indictment]]></category>
		<category><![CDATA[inertia]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[Jyoti]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[Mirdha]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[mouse]]></category>
		<category><![CDATA[Netherlands]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[slovakia]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2050</guid>
		<description><![CDATA[Bribing doctors by the pharmaceutical companies directly or indirectly, as reported frequently by the media all over the world, including India, to prescribe their respective brand of drugs has now reached an alarming proportion, jeopardizing patients’ interest, seriously more than &#8230; <a href="http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MCI asks Doctors to Prescribe Medicines in Generic Names</title>
		<link>http://www.tapanray.in/mci-asks-doctors-to-prescribe-drugs-in-generic-names/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=mci-asks-doctors-to-prescribe-drugs-in-generic-names</link>
		<comments>http://www.tapanray.in/mci-asks-doctors-to-prescribe-drugs-in-generic-names/#comments</comments>
		<pubDate>Mon, 28 Jan 2013 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[building]]></category>
		<category><![CDATA[circular]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Forbes]]></category>
		<category><![CDATA[formulations]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Spain]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[unethical]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1459</guid>
		<description><![CDATA[Last week, on January 21, 2013, in a circular addressed to the Dean/Principals of all the Medical Colleges, Director of all the hospitals and Presidents of all the State Medical Councils, the Medical Council of India (MCI) called upon the &#8230; <a href="http://www.tapanray.in/mci-asks-doctors-to-prescribe-drugs-in-generic-names/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/mci-asks-doctors-to-prescribe-drugs-in-generic-names/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Havoc’ and its ‘Aftermath’: Clinical Trials in India</title>
		<link>http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=havoc-and-its-aftermath-clinical-trials-in-india</link>
		<comments>http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/#comments</comments>
		<pubDate>Mon, 14 Jan 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[aftermath]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[death]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[havoc]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[Parialmentary]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[volunteer]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1427</guid>
		<description><![CDATA[Just as the New Year dawned, on January 3, 2013, in an embarrassing indictment to the Government, the bench of honorable justices R.M Lodha and A.R Dave of the Supreme Court reportedly observed that uncontrolled Clinical Trials (CT) are creating &#8230; <a href="http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/havoc-and-its-aftermath-clinical-trials-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quick implementation of the undiluted ‘Central Drug Authority (CDA)’ Bill is essential for emerging India</title>
		<link>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india</link>
		<comments>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/#comments</comments>
		<pubDate>Mon, 21 Feb 2011 00:30:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=299</guid>
		<description><![CDATA[Many industry experts after having evaluated the provisions of the original draft proposal for forming a Central Drugs Authority (CDA) in the country, commended and supported this laudable initiative of the Government. This Bill also known as, “The Drugs &#38; &#8230; <a href="http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
